Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16B* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.3892298EPITOPES HAVING SEQUENCE HOMOLOGY TO CORONAVIRUS SPIKE PROTEIN SUBUNIT AND USES THEREOF
EP 13.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 20169101 Applicant PREVIPHARMA CONSULTING GMBH Inventor KIESSIG STEPHAN T
The present invention relates to polypeptides comprising epitopes having a sequence homology to a sequence section of subunit S1 and/or subunit S2 of coronavirus spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the present invention refers to a vaccine comprising such polypeptide. The invention further relates to an antibody binding to subunit S1 and/or subunit S2 and to methods for isolating and detecting such antibody and to uses of the polypeptides and antibodies.
2.WO/2021/237292METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
WO 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/AU2021/050507 Applicant GENETIC TECHNOLOGIES LIMITED Inventor DITE, Gillian Sue
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection.
3.WO/2021/216615HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION
WO 28.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/028245 Applicant THE GENERAL HOSPITAL CORPORATION Inventor GAIHA, Gaurav
A method of preventing or treating COVID infection in a subject includes selecting two or more COVED CTL epitopes from a Coronavirus proteome that have a network score that meets a threshold value. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected Coronavirus CTL epitopes.
4.20210388031Designer Peptide Opsonins
US 16.12.2021
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 17348994 Applicant New Jersey Institute of Technology Inventor Dr. Vivek A. Kumar

Disclosed is a new strategy, composition, and method for a self-assembling peptides (SAP) that will self-assemble atop COVID-19 for immune destruction and act as a functional COVID-19 opsonin. The designed self-assembling peptides bind and assemble atop SARS-CoV-2—providing a new mechanism of infection abrogation. One benefit is avoidance of side effects that other formulations or repurposed drugs contain. Other feature of this technology include: (a) (SAP) are composed of L-amino acids that are highly biocompatible sub-Q, IM and IV (no adverse reaction for 10% blood volume replacement with 1 w % peptide in mice or rats); (b) Highly targeted approach that binds to viral particles preventing side effects; (c) SAP are intrinsically biodegradable and endocytosed; (d) SAP bound COVID-19 may promote engulfment, clearance, and antigen presentation (for immunity development); and (e) targeting the spike protein with SAP may allow treatment of other coronaviruses.

5.202121036722DEEP LEARNING MODEL FOR PREDICTING SEVERITY PROGNOSIS IN PATIENTS INFECTED WITH COVID-19
IN 31.12.2021
Int.Class G06N /
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
NCOMPUTER SYSTEMS BASED ON SPECIFIC COMPUTATIONAL MODELS
Appl.No 202121036722 Applicant Dr. Jambi Ratna Raja Kumar (Associate Professor Inventor Dr. Jambi Ratna Raja Kumar (Associate Professor
ABSTRACTOur Invention Machine Learning Model for Predicting Severity Prognosis in Patients Infected with COVID-19.cis to the very new coronavirus, that began to be known as SARS-CoV-2, could be a advanced fiber polymer beta coronavirus, at first known in metropolis (Hubei province, China) and presently spreading across six continents inflicting a substantial hurt to patients, with no specific tools as yet to produce prognostic outcomes. The Invention is to gauge potential findings on chest CT of patients with signs and symptoms of metabolic process syndromes and positive epidemiologic factors for COVID-19 infection and to correlate them with the course of the sickness. during this sense, it's conjointly expected to develop specific ML- machine learning formula for this purpose, through pneumonic segmentation, which may predict potential prognostic factors, through a lot of correct results. Our various hypothesis is that the machine learning model supported clinical, tomography and epidemiologic information are going to be able to predict the severity prognosis of patients infected with COVID-19. we'll perform a multicenter retrospective longitudinal study to get an outsized variety of cases in a very short amount of your time, for higher study validation.
6.WO/2021/096980METHODS AND SYSTEMS FOR IDENTIFYING, CLASSIFYING, AND/OR RANKING GENETIC SEQUENCES
WO 20.05.2021
Int.Class G16B 10/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
10ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
Appl.No PCT/US2020/060045 Applicant REGENERON PHARMACEUTICALS, INC. Inventor COPIN, Richard
The present disclosure provides methods and systems for analysis of genomic sequence information. The present disclosure provides, among other things, methods and systems for characterizing sequence conservation. As is discussed herein, certain methods and systems of the present disclosure include assignment of a similarity score to a sequence or pairwise sequence comparison based on a measure of coverage and a measure of identity between two aligned sequences.
7.WO/2021/226520PEPTIDE COMPOSITIONS FOR THE TREATMENT OF PATHOGENIC INFECTIONS
WO 11.11.2021
Int.Class A61K 38/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/US2021/031387 Applicant KIROMIC BIOPHARMA, INC. Inventor CHIRIVA-INTERNATI, Maurizio
The technology relates in part to peptide compositions, including peptide vaccine compositions, for the treatment of a disease or condition caused by a pathogen, such as a virus, including coronaviruses such as SARS-CoV-2. The technology also relates in part to methods of selecting peptides for preparing the compositions, and to methods of treatment, including prophylactic treatment, using the compositions.
8.202131015870HAMAMELITANNIN AND ROSMARINIC ACID AS COVID-19 INHIBITORS
IN 07.05.2021
Int.Class C07D /
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
Appl.No 202131015870 Applicant Rajesh Kumar Das Inventor Rajesh Kumar Das
The present invention relates to identifying and screening best phytochemicals as potent inhibitors against COVID-19as it was recently, caused the outbreak situation of global public health. For this research we choose two standard drugs namely hamamelitannin and rosmarinic acid as a probable inhibitor of pandemic COVID-19 receptor as compared to antimalarial drug hydroxychloroquine, anti-viral drug remdesivir and also baricitinib. This study was done by taking into consideration of molecular docking study, performed with Auto Dock 4.0 (AD4.0). The results shown protein-ligand interaction of hamamelitannin and rosmarinic acid showing comparable binding energies than that of clinically applying probable COVID-19 inhibitors hydroxychloroquine (an anti-malarial drug) and remdesivir (an anti-viral drug).
9.202111002831“DISCOVEY OF IMATINIB A DRUG FOR TREATING CORONAVIRIDAE FAMILY OF VIRUS”
IN 12.02.2021
Int.Class G16C /
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
Appl.No 202111002831 Applicant Dr. Vishal M. Balaramnavar Inventor Dr. Vishal M. Balaramnavar
A method (300) for identifying a binding site of an Imatinib drug, the method comprising:developing pharmacophore models to extract features from the Imatinib drug;validating the developed pharmacophore models by comparing with pre-defined models of existing coronavirus drugs;performing a ligand-based virtual screening (first virtual screening) of a database of drugs with the validated pharmacophore models; performing a structure-based virtual screening (second virtual screening) of the validated pharmacophore models by structural docking of a target protein into the validated pharmacophore models; assigning a score to each pharmacophore model of the Imatinib drugin order to identify the validated pharmacophore models with a high binding affinity and efficiency; and comparing the score obtained from the ligand-based virtual screening (first virtual screening) and the structure-based virtual screening (second virtual screening) for classifying the scored pharmacophore models based on the target protein binding affinity and efficiency for the coronaviridae family of virus.
10.20210402392APPARATUS AND METHOD FOR POINT OF CARE, RAPID, FIELD-DEPLOYABLE DIAGNOSTIC TESTING OF COVID-19, VIRUSES, ANTIBODIES AND MARKERS, AUTOLAB 20
US 30.12.2021
Int.Class B01L 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
3Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
Appl.No 17083113 Applicant Autonomous Medical Devices, Inc. Inventor Josh Shachar

An automated system communicated to a remote server for diagnostically field testing a sample taken from a patient using an automated portable handheld instrument to determine the presence of Covid-19 and/or antibodies thereto includes microfluidic circuits defined in a rotatable disk for performing a bioassay using a microarray to generate an electrical signal indicative of a bioassay measurement; the microarray operationally positioned in the microfluidic circuit; one or more lasers; one or more positionable valves in the microfluidic circuit; and a backbone unit for rotating the disk according to a protocol to perform the bioassay, for controlling the lasers to selectively open the positionable valves in the microfluidic disk, for operating the microarray to generate a digital image as a bioassay measurement; for communicating the bioassay measurement to the remote server, and for associating the performed bioassay and its corresponding bioassay measurement to the patient.